Jurriën M. ten Berg

49.1k total citations · 8 hit papers
416 papers, 13.7k citations indexed

About

Jurriën M. ten Berg is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Jurriën M. ten Berg has authored 416 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 365 papers in Cardiology and Cardiovascular Medicine, 154 papers in Surgery and 68 papers in Internal Medicine. Recurrent topics in Jurriën M. ten Berg's work include Antiplatelet Therapy and Cardiovascular Diseases (210 papers), Acute Myocardial Infarction Research (148 papers) and Atrial Fibrillation Management and Outcomes (122 papers). Jurriën M. ten Berg is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (210 papers), Acute Myocardial Infarction Research (148 papers) and Atrial Fibrillation Management and Outcomes (122 papers). Jurriën M. ten Berg collaborates with scholars based in Netherlands, Germany and United States. Jurriën M. ten Berg's co-authors include Jochem W. van Werkum, Arnoud W.J. van ‘t Hof, Johannes C. Kelder, Heleen Bouman, Nicoline J. Breet, Christian M. Hackeng, Freek W.A. Verheugt, Vera H.M. Deneer, Benno J. Rensing and Willem J.M. Dewilde and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jurriën M. ten Berg

399 papers receiving 13.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

2013 1.1k citations Willem J.M. Dewilde, Freek W.A. Verheugt et al. profile →
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

2017 843 citations Christopher P. Cannon, Deepak L. Bhatt et al. New England Journal of Medicine profile →
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation

2010 636 citations Nicoline J. Breet, Jochem W. van Werkum et al. profile →
Predictors of Coronary Stent Thrombosis

2009 480 citations Jochem W. van Werkum, Antonius A.C.M. Heestermans et al. Journal of the American College of Cardiology profile →
A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

2019 378 citations Daniel M.F. Claassens, Gerrit J.A. Vos et al. New England Journal of Medicine profile →
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

2013 378 citations Dariusz Dudek, Christian W. Hamm et al. New England Journal of Medicine profile →
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

2020 212 citations Rik Hermanides, Thomas O. Bergmeijer et al. profile →
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

2022 163 citations Diana A. Gorog, Gemma Vilahur et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jurriën M. ten Berg Netherlands	55	11.9k	5.1k	2.7k	1.2k	983	416	13.7k
Christopher P. Cannon United States	39	11.2k 0.9×	5.3k 1.1×	3.0k 1.1×	1.3k 1.1×	525 0.5×	109	12.4k
Diego Ardissino Italy	41	9.0k 0.8×	4.5k 0.9×	2.1k 0.8×	1.7k 1.4×	509 0.5×	217	11.1k
Witold Rużyłło Poland	39	10.0k 0.8×	7.3k 1.4×	1.7k 0.6×	2.1k 1.7×	856 0.9×	172	14.1k
Harald Darius Germany	43	11.8k 1.0×	5.2k 1.0×	4.5k 1.6×	956 0.8×	2.2k 2.2×	202	17.9k
Allan M. Skene United Kingdom	27	10.2k 0.9×	6.6k 1.3×	1.9k 0.7×	1.3k 1.1×	719 0.7×	36	14.2k
C. Michael Gibson United States	53	11.8k 1.0×	6.8k 1.4×	2.2k 0.8×	3.9k 3.2×	1.0k 1.0×	220	15.1k
Felicita Andreotti Italy	45	10.1k 0.8×	5.8k 1.2×	1.5k 0.5×	2.6k 2.2×	1.2k 1.2×	179	15.2k
Shinya Goto Japan	63	10.7k 0.9×	4.2k 0.8×	3.8k 1.4×	985 0.8×	1.7k 1.7×	293	15.2k
Shamir R. Mehta Canada	49	13.2k 1.1×	7.5k 1.5×	4.0k 1.5×	2.4k 2.0×	493 0.5×	226	16.1k
Paul A. Gurbel United States	63	14.1k 1.2×	8.0k 1.6×	4.5k 1.7×	820 0.7×	832 0.8×	419	17.7k

Countries citing papers authored by Jurriën M. ten Berg

Since Specialization

Citations

This map shows the geographic impact of Jurriën M. ten Berg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jurriën M. ten Berg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jurriën M. ten Berg more than expected).

Fields of papers citing papers by Jurriën M. ten Berg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jurriën M. ten Berg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jurriën M. ten Berg. The network helps show where Jurriën M. ten Berg may publish in the future.

Co-authorship network of co-authors of Jurriën M. ten Berg

This figure shows the co-authorship network connecting the top 25 collaborators of Jurriën M. ten Berg. A scholar is included among the top collaborators of Jurriën M. ten Berg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jurriën M. ten Berg. Jurriën M. ten Berg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sandner, Sigrid, Björn Redfors, Kevin R. An, et al.. (2024). Coronary Artery Bypass Graft Failure in Women. Journal of the American College of Cardiology. 84(2). 182–191. 9 indexed citations

Fabris, Enrico, et al.. (2024). Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial. European Heart Journal Acute Cardiovascular Care. 13(8). 595–601. 1 indexed citations

Vlaar, Pieter J., Marleen van Wely, Lokien X. van Nunen, et al.. (2024). Upper- vs Lower-Extremity Secondary Access During Transcatheter Aortic Valve Implantation. JAMA Network Open. 7(10). e2438578–e2438578. 3 indexed citations

Bor, Willem L., et al.. (2022). Hemostatic biomarkers and antithrombotic strategy in percutaneous left atrial interventions: State-of-the-art review. Thrombosis Research. 215. 41–51. 5 indexed citations

Yin, Dean R.P.P. Chan Pin, Joyce Peper, Melvyn Tjon Joe Gin, et al.. (2022). External validation of the GRACE risk score and the risk–treatment paradox in patients with acute coronary syndrome. Open Heart. 9(1). e001984–e001984. 11 indexed citations

Berg, Jurriën M. ten, Dirk Sibbing, Bianca Rocca, et al.. (2021). Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. European Heart Journal. 42(23). 2265–2269. 75 indexed citations

Claassens, Daniel M.F., Renicus S. Hermanides, Gerrit J.A. Vos, et al.. (2021). Efficacy and safety of glycoproteinIIb/IIIainhibitors in addition toP2Y₁₂inhibitors inST‐segment elevation myocardial infarction: A subanalysis of thePOPularGenetics trial. Catheterization and Cardiovascular Interventions. 99(3). 676–685. 4 indexed citations

Bor, Willem L., Saman Rasoul, E. Kaplan, et al.. (2021). Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry. BMC Cardiovascular Disorders. 21(1). 292–292. 2 indexed citations

Mahmoodi, Bakhtawar K., Niclas Eriksson, Gerrit J.A. Vos, et al.. (2021). Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis. Journal of the American Heart Association. 10(11). e020025–e020025. 3 indexed citations

10.

Yin, Dean R.P.P. Chan Pin, Marco Valgimigli, Stephan Windecker, et al.. (2020). Patient-tailored antithrombotic therapy following percutaneous coronary intervention. European Heart Journal. 42(10). 1038–1046. 22 indexed citations

11.

Caterina, Raffaele De, Dimitar Raev, Shamir R. Mehta, et al.. (2020). Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. The American Journal of Medicine. 133(11). 1302–1312. 3 indexed citations

12.

Zivelonghi, Carlo, J.P. van Kuijk, Enrico Poletti, et al.. (2019). A “minimalistic hybrid algorithm” in coronary chronic total occlusion revascularization: Procedural and clinical outcomes. Catheterization and Cardiovascular Interventions. 95(1). 97–104. 11 indexed citations

13.

Claassens, Daniel M.F., Gerrit J.A. Vos, Thomas O. Bergmeijer, et al.. (2019). A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. New England Journal of Medicine. 381(17). 1621–1631. 378 indexed citations breakdown →

14.

Hermanides, Renicus S., Jan Paul Ottervanger, Jurriën M. ten Berg, et al.. (2012). Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.. PubMed. 24(3). 84–9. 6 indexed citations

15.

Lip, Gregory Y.H., Piotr Ponikowski, Stefan D. Anker, et al.. (2012). Thrombo-Embolism and Antithrombotic Therapy for Heart Failure in Sinus Rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure. 14(7). 681–695. 54 indexed citations

16.

Erlinge, David, Jurriën M. ten Berg, David P. Foley, et al.. (2012). PRASUGREL 5 MG IN LOW BODY WEIGHT PATIENTS REDUCES PLATELET REACTIVITY TO A SIMILAR EXTENT AS PRASUGREL 10 MG IN HIGHER BODY WEIGHT PATIENTS: RESULTS FROM THE FEATHER TRIAL. Journal of the American College of Cardiology. 59(13). E341–E341. 4 indexed citations

17.

Brar, Somjot, Jurriën M. ten Berg, Rossella Marcucci, et al.. (2011). Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 58(19). 1945–1954. 327 indexed citations

18.

Branden, Ben J L Van den, Martijn C. Post, H. W. M. Plokker, Jurriën M. ten Berg, & Maarten J. Suttorp. (2010). Percutaneous Atrial Shunt Closure Using the Novel Occlutech Figulla Device: 6‐Month Efficacy and Safety. Journal of Interventional Cardiology. 24(3). 264–270. 19 indexed citations

19.

Werkum, Jochem W. van, Antonius A.C.M. Heestermans, Johannes C. Kelder, et al.. (2009). Long-Term Clinical Outcome After a First Angiographically Confirmed Coronary Stent Thrombosis. Circulation. 119(6). 828–834. 113 indexed citations

20.

Berg, Jurriën M. ten, Wim B. Gerritsen, Fred J.L.M. Haas, et al.. (2002). High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thrombosis Research. 105(5). 385–390. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact